Deal Makers of Japan, Volume 2
We are pleased to present the second series of the Deal Makers of Japan – Exclusive Interviews with Japan’s best dealmakers.
Asian Capabilities, White Papers
2020
Uncategorized
Panel Recording on 6.11: Accessing Capital in the Time of COVID
Danforth Advisors, Locust Walk, and Mintz joined on Thursday, June 11th from 2-3pm EST for the panel, “Accessing Capital in the Time of COVID: Challenges, Opportunities, and Best Practices.”
Uncategorized
Panel Recording on 5.7: Biopharma Deal Maker’s Guide to Strategic Partnerships
Thank you to all that joined us on Thursday, May 7th for our live panel discussion where we took a deep dive into biopharma deal marker’s best practices for strategic partnerships.
Uncategorized
Panel Recording on 4.16: Q1 2020 Biopharma Market Conditions Live Panel
Thank you to all that joined us on Thursday, April 16th for our live panel discussion where we took a deep dive into Q1 2020 biopharma market conditions, and in particular, how COVID-19 has played a role in the impact.
Uncategorized
LIVE Panel Discussion: Q1 2020 Biopharma Market Conditions
Please join us Thursday, April 16th from 2-3 pm EST where our team will dive into Q1 2020 market conditions with a lens on partnerships, financings, and insight
Uncategorized
Panel Recording on 4.2: Strategic Implications of COVID-19 on Biopharma Companies & Investors
Thank you to all that joined us on Thursday, April 2nd for our live panel discussion where we took a deep dive into the strategic implications of COVID-19 on biopharma companies and investors.
Uncategorized
LIVE Panel Discussion, COVID-19: Strategic Implications on Biopharma
Please join us Thursday, April 2nd from 1-2 PM EST to listen to the LIVE panel, COVID 19: Strategic Implications on Biopharma.
Market Trends, White Papers
Strategic Implications of COVID-19 on Biopharma
hese are challenging times for governments, public health administrations and the financial markets. While each biopharma company’s primary concern is the health and safety of its team members
Partnering, White Papers
Deal Theory: a Biopharma Deal Maker’s Approach to Maximizing Strategic Partnerships
In the summer of 2019, Locust Walk launched a blog post, Financing overhang or hangover: The impact on partnerships for public biotech companies, that was born out of observations and conversations with many public, non-revenue generating biotech companies over the years.
Asian Capabilities, White Papers
Deal Makers of Japan, Volume 1
Locust Walk has been active in Asia, in particular, Japan for nearly half of the firm’s history and we are deeply rooted in the market. We have advised on more than a dozen transactions during our history in Japan and have successfully helped deal making between US/EU companies and Japan pharma.